BioCentury | Mar 1, 2019
Financial News

Syncona leads CHF35M A round for Anaveon

...protein Proleukin aldesleukin for melanoma and renal cancer, and Eisai Co. Ltd. (Tokyo:4523) has Ontak denileukin diftitox...
BioCentury | Feb 26, 2019
Financial News

Syncona leads CHF35 million A round for Anaveon

...protein Proleukin aldesleukin for melanoma and renal cancer, and Eisai Co. Ltd. (Tokyo:4523) has Ontak denileukin diftitox...
BioCentury | Apr 24, 2014
Targets & Mechanisms

Leveling cancer with IL-15

...RCC). Eisai Co. Ltd. markets Ontak denileukin diftitox for cutaneous T cell lymphoma (CTCL). Proleukin and Ontak...
BioCentury | Aug 15, 2011
Clinical News

Ontak denileukin diftitox: Phase III started

...1Q11 earnings ending June 30 that it began a U.S. Phase III trial to evaluate Ontak...
...in patients who express CD25 . Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Product: Ontak denileukin diftitox...
BioCentury | Feb 28, 2011
Product Development

Two for one in neuroblastoma

...IL-2 from Novartis AG to treat metastatic melanoma and renal cell carcinoma (RCC), and Ontak denileukin diftitox...
BioCentury | Jul 15, 2010
Targets & Mechanisms

Fixing vascular leak in IL-2 immunotherapy

...'s Proleukin aldesleukin IL-2 to treat metastatic melanoma and renal cell carcinoma (RCC) and Ontak denileukin diftitox...
BioCentury | Jun 24, 2010
Distillery Therapeutics

Indication: Cancer

...Proleukin aldesleukin IL-2 from Novartis AG is marketed to treat melanoma and renal cancer. Ontak denileukin diftitox...
BioCentury | May 31, 2010
Clinical News

Ontak denileukin diftitox: Phase II data

...In the open-label, U.S. Phase II CONCEPT trial in 49 patients with newly-diagnosed PTCL, Ontak plus...
...will be presented at the American Society of Clinical Oncology meeting in Chicago in June. Ontak...
...whose malignant cells express CD25 . Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Product: Ontak denileukin diftitox...
BioCentury | Dec 14, 2009
Strategy

Solid grip on liquid cancers

...Also on the market are Ontak denileukin diftitox and Targretin bexarotene, both from Eisai Co. Ltd. Ontak...
BioCentury | Nov 9, 2009
Strategy

Folotyn Follows Price Signals

...get treated with B cell lymphoma regimens given off label," such as Rituxan rituximab, Ontak denileukin diftitox...
...by Roche , its Genentech Inc. unit and Biogen Idec Inc. Eisai Co. Ltd. markets Ontak...
Items per page:
1 - 10 of 99